Section 01
What it's used for
Approved for bladder pain
Approved by the FDA (as Elmiron) for interstitial cystitis/bladder pain syndrome. A trial and meta-analysis found better symptom scores than placebo (RR=2.07). A 2026 review notes most trials in this field failed, so evidence is mixed.
▸Clinical wording
Pentosan polysulfate is FDA-approved as Elmiron for interstitial cystitis/bladder pain syndrome (IC/BPS). A randomized, placebo-controlled trial and an accompanying meta-analysis found a statistically significant improvement in symptom index scores versus placebo (RR=2.07, 95% CI 1.37-3.13). A broader 2026 review of NIDDK-funded studies on urologic chronic pain conditions notes that most clinical trials in this field have not produced positive results, so the overall evidence for symptom benefit is more mixed than a single positive trial implies.
Joint cartilage in osteoarthritis
As Cartrophen Vet, this drug is approved in Australia only for animals. In a small human trial (61 people) with knee arthritis, it significantly lowered a cartilage-breakdown marker at day 56 and 168. A dog study also found joint benefits.
▸Clinical wording
Pentosan polysulfate sodium (Cartrophen Vet) is registered as a veterinary medicine in Australia through the Australian Pesticides and Veterinary Medicines Authority, not the Therapeutic Goods Administration, which regulates only human therapeutics. In a phase 2, placebo-controlled human trial in moderate-to-severe knee osteoarthritis (n=61), pentosan polysulfate significantly reduced the cartilage-degradation biomarker ARGS/aggrecan versus placebo at day 56 (p=0.028) and day 168 (p=0.024). A separate animal study in dogs with naturally occurring osteoarthritis also found benefits to joint structure and function over six months, supporting chondroprotective effects across species.
Prion disease, early research
Pentosan polysulfate is being studied for stopping prion proteins from clumping together, the misfolding process thought to drive prion diseases like CJD. The available summary gives no trial or animal-study details.
▸Clinical wording
Research suggests PPS may inhibit prion protein aggregation.
Section 02
Mechanism of Action
Patching the bladder's protective lining
- The bladder lumen is coated by sugar chains that trap water and make the lining nearly impermeable.
- When that coat is lost, potassium in urine reaches nerve and muscle and depolarises them.
- In mice labelled sugar chains bound damaged surface heavily and intact bladder barely at all; in rats they restored permeability.
- Both studies used chondroitin sulfate as the probe, not the drug itself, so they show the principle only.
▸Clinical wording
Restoration of the urothelial glycosaminoglycan barrier
The bladder lumen is coated by anionic glycosaminoglycans that trap water and make the urothelium nearly impermeable; when the coat is lost, urinary potassium reaches nerve and muscle and depolarises them (Parsons, Urology 2007, clinical review). In mice stripped with trypsin or acid, labelled glycosaminoglycan bound extensively to damaged surface and almost not at all to intact bladder (Kyker, BMC Urology 2005); in acid-damaged rat bladder it returned permeability to intravesical 86-Rb to control values (Hauser, J Urol 2009). Both used chondroitin sulfate as the probe, not PPS itself, so they establish the coating principle rather than PPS-specific binding.
Holding back histamine-releasing immune cells
- The compound blocked histamine release from rat immune cells dose-dependently, whatever triggered the release.
- The block appeared within a minute, needed no pre-incubation and persisted after washing out.
- It was more potent than the comparison drug cromolyn and, unlike it, did not fade on repeat exposure.
- Imaging showed lowered calcium inside the cells, proposed as the immediate cause of the block.
▸Clinical wording
Mast cell stabilisation and suppression of histamine release
Pentosan polysulfate inhibited histamine release from rat mast cells dose-dependently, whether secretion was triggered by compound 48/80, substance P, or IgE plus antigen; inhibition was documented by light and electron microscopy, was more potent than disodium cromoglycate, appeared within one minute, did not require pre-incubation, and persisted after washout, while cromolyn showed rapid tachyphylaxis (Chiang, J Urol 2000). Unlike cromolyn, PPS also blocked secretion from mucosal mast cells and rat basophilic leukaemia cells. Confocal imaging with a calcium indicator dye showed PPS lowered intracellular calcium, proposed as the proximal cause of the secretory block.
Blocking cartilage-cutting enzymes from the side
- The compound binds non-cutting parts of two cartilage-degrading enzymes and blocks them at very low concentrations.
- It only weakly affects a simplified test substrate, the signature of binding away from the active site.
- It also raises a natural enzyme brake (TIMP-3) in cartilage by stopping cells from swallowing it.
- In cartilage from mice lacking that brake, the protection against cartilage loss was absent.
▸Clinical wording
Exosite inhibition of aggrecanases and rescue of TIMP-3
Calcium pentosan polysulfate binds the non-catalytic spacer domain of ADAMTS-4 and the cysteine-rich domain of ADAMTS-5 and blocks cleavage of aggrecan with IC50 values of 10-40 nM, while only weakly inhibiting hydrolysis of a non-glycosylated recombinant substrate - the signature of an exosite rather than an active-site inhibitor (Troeberg, FASEB J 2008, in vitro and cartilage explants). The same work showed CaPPS raises cartilage TIMP-3 by blocking its LRP-mediated endocytosis and increases TIMP-3 affinity for ADAMTS-4 and -5 more than 100-fold; in TIMP-3-null mouse cartilage the protection against aggrecan loss was absent.
Pushing cartilage cells to rebuild
- The compound supports building activity in cartilage cells and reduces catabolic loss of cartilage matrix.
- It enters those cells and binds gene-control proteins, altering expression of matrix-degrading enzymes.
- Joint-lining cells made normal amounts of large lubricating hyaluronan again in arthritic rat joints.
- Cell culture shows it stimulating proteoglycan production by cattle and sheep cartilage cells.
▸Clinical wording
Chondrocyte and synoviocyte anabolic responses
Sodium and calcium pentosan polysulfate support chondrocyte anabolic activity and attenuate catabolic loss of cartilage matrix; beyond direct enzyme inhibition, the compounds enter chondrocytes and bind promoter proteins, altering matrix metalloproteinase gene expression (Ghosh, Semin Arthritis Rheum 1999, review of rabbit, canine and ovine models). Synoviocyte synthesis of high-molecular-weight hyaluronan, reduced in osteoarthritis, was normalised by incubation with PPS or by intra-articular injection into arthritic rat joints. Cell-culture work shows PPS stimulating proteoglycan synthesis by bovine and ovine chondrocytes with or without IL-1 (Smith and Melrose, Pharmaceuticals 2023).
Imitating a natural sugar coating
- As a sulfated plant sugar the compound mimics a natural cell-surface sugar and binds several growth factors.
- It matches heparin in boosting one growth factor's effect on cultured blood vessel lining cells.
- It also prompts those cells to release clot-dissolving and fat-processing enzymes, unlike heparin's anticoagulant profile.
- In mice infected with two joint-affecting viruses, it preserved cartilage proteoglycan.
▸Clinical wording
Heparan sulfate mimicry at growth factor and endothelial targets
As a sulfated xylan, PPS behaves as a heparan sulfate mimetic: it binds fibroblast growth factors, midkine and pleiotrophin, engages the heparin-binding site of FGFR1, and matches heparin in potentiating acidic FGF mitogenic activity on cultured endothelial cells (Smith and Melrose, Pharmaceuticals 2023). PPS also stimulates endothelial release of tissue plasminogen activator, superoxide dismutase and lipases while lowering plasma PAI-1, a thrombolytic and lipolytic profile distinct from heparin anticoagulation (Ghosh, Semin Arthritis Rheum 1999). In mice infected with Ross River or chikungunya virus, PPS preserved cartilage proteoglycan (Herrero, J Virol 2015).
Section 03
Biological Pathways
- GAG barrier restorationThe bladder lining is coated by glycosaminoglycans blocking urinary potassium from reaching nerve and muscle; animal studies showed this coating with a glycosaminoglycan probe, not PPS (Kyker 2005; Hauser 2009).
- Mast cell stabilizationPPS inhibited histamine release from rat mast cells regardless of trigger, acting within a minute without pre-incubation, more potent than disodium cromoglycate and without its tachyphylaxis (Chiang, J Urol 2000).
- Aggrecanase exosite inhibitionCalcium PPS binds a spacer domain on ADAMTS-4/-5, blocking aggrecan cleavage at 10-40 nM while rescuing TIMP-3 from receptor-mediated endocytosis, protection absent in TIMP-3-null mice (Troeberg 2008).
- Chondrocyte and synoviocyte anabolismPPS enters chondrocytes to alter MMP gene expression, normalizes synoviocyte hyaluronan synthesis, and stimulates proteoglycan synthesis with or without IL-1 (Ghosh 1999; Smith and Melrose 2023).
- Heparan sulfate mimicryAs a sulfated xylan, PPS binds fibroblast growth factors and engages FGFR1 like heparin, raising endothelial tPA release and lowering PAI-1, a profile distinct from anticoagulation (Ghosh 1999).
Section 04
Dosage Information
| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Oral — the approved dose | FDA label — interstitial cystitis (bladder pain) | 300 mg a day — one 100 mg capsule three times daily, 1 hour before or 2 hours after meals; about 3.3–4.3 mg/kg for a 70–90 kg adult. | The label reviews at 3 months, allows 3 more, then says the value and risks past 6 months are unknown. The daily dose is fixed; the years on it are not. |
| Oral — total taken over years | Eye damage reports and screening studies | At the label dose about 110 g builds up a year. Retinal damage risk passed 10% at 500–999 g — 4.5 to 9 years — and 50% above 1,500 g. | The total, not the number on the bottle, decides the outcome. The label ties risk to it, puts most cases past 3 years, and warns damage may be permanent. |
| Oral — trial comparing doses | Randomised double-blind trial, 380 adults, 32 weeks | 300, 600 or 900 mg a day — about 3.3–4.3, 6.7–8.6 or 10–12.9 mg/kg a day for a 70–90 kg adult. | Response was the same at all three doses: how long it was taken mattered more than how much. The higher doses tripled the total and relieved no more symptoms. |
Results
Syringe Fill Level (100u syringe)
Set positive values for: Recommended dose per kg.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Section 05
Protocols
No protocols featuring this peptide yet. Browse All Protocols
Section 06
Stability & Storage
Storing the product
Oral capsules (Elmiron, 100 mg) and the veterinary injectable form are both stored at room temperature. Pentosan polysulfate is a stable compound with a shelf life of 3 or more years.
After opening
No separate post-opening timeframe is specified for either form. Both are kept at room temperature and used within the stated shelf life, which depends on the batch and storage conditions.
Section 07
Side Effects & Precautions
GI effects (nausea, diarrhea, 4%), alopecia (4%), headache. Maculopathy (pigmentary retinal changes) identified with long-term use (>3 years) — requires ophthalmological monitoring. Mild anticoagulant effect — use caution with blood thinners.
Section 08
Regulatory Status
Long-term use carries a labelled risk of a distinctive retinal condition, and prescribers are expected to screen for it.
FDA / United States
Approved for interstitial cystitis
Elmiron was approved in 1996 as the only oral drug specifically indicated for the relief of bladder pain or discomfort associated with interstitial cystitis; it remains available by prescription only.
Safety label update
Labelled for a vision risk since 2020
In June 2020 the FDA added a warning about pigmentary maculopathy — a retinal condition tied to cumulative dose and duration of use — and now recommends a baseline eye exam before starting treatment and periodic exams during it.
EMA / European Union
Authorised, with its own schedule
Elmiron holds an EU-wide marketing authorisation; its EU product information recommends a retinal examination after five years of use, or sooner if visual symptoms appear, and yearly exams once pigmentary changes are found.
WADA
Not prohibited
Pentosan polysulfate does not appear anywhere on the 2026 Prohibited List or the 2026 Monitoring Program.
Approval and a prescription-only label are not the same as a clean safety record — the vision-related warning is a genuine, still-current condition of continued use, not a formality, and anyone on long-term treatment should keep to the recommended eye-exam schedule.
Section 09
Research Studies
- [1]The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritisParsons CL. · Urology · 2007
- [2]Exogenous glycosaminoglycans coat damaged bladder surfaces in experimentally damaged mouse bladderKyker KD, Coffman J, Hurst RE. · BMC Urology · 2005
- [3]Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfateHauser PJ, Buethe DA, Califano J, Sofinowski TM, Culkin DJ, Hurst RE. · The Journal of Urology · 2009
- [4]Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitisChiang G, Patra P, Letourneau R, Jeudy S, Boucher W, Green M, Sant GR, Theoharides TC. · The Journal of Urology · 2000
- [5]Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanasesTroeberg L, Fushimi K, Khokha R, Emonard H, Ghosh P, Nagase H. · The FASEB Journal · 2008
- [6]The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatmentGhosh P. · Seminars in Arthritis and Rheumatism · 1999
- [7]Pentosan polysulfate affords pleotropic protection to multiple cells and tissuesSmith MM, Melrose J. · Pharmaceuticals · 2023
- [8]Pentosan polysulfate: a novel glycosaminoglycan-like molecule for effective treatment of alphavirus-induced cartilage destruction and inflammatory diseaseHerrero LJ, Foo SS, Sheng KC, Chen W, Forwood MR, Bucala R, Mahalingam S. · Journal of Virology · 2015
- [9]Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodiumPearce WA, Chen R, Jain N. · Ophthalmology · 2018
Section 10
Frequently Asked Questions
Pentosan polysulfate sodium is a semi-synthetic sulfated polysaccharide made from beech wood, chemically similar to heparin. It has been FDA-approved since 1996 as Elmiron, an oral capsule for interstitial cystitis/bladder pain syndrome, and is separately registered in Australia as a veterinary product (Cartrophen Vet) for osteoarthritis in animals.
For bladder pain, it's thought to help rebuild the protective glycosaminoglycan coating on the bladder lining and to dose-dependently block histamine release from mast cells, effects shown with related glycosaminoglycans and with pentosan polysulfate itself in animal and cell studies. For cartilage, it binds a non-active site on the ADAMTS-4 and ADAMTS-5 enzymes that break down cartilage and blocks them with nanomolar potency in cartilage explants. These are two largely separate lines of evidence, not one mechanism covering both uses.
The FDA label for interstitial cystitis is 300 mg a day, split into three 100 mg capsules an hour before or two hours after meals — about 3.3 to 4.3 mg/kg for a 70–90 kg adult. A 380-person trial comparing 300, 600 and 900 mg a day found no extra symptom relief at the higher doses; how long it was used mattered more than how much.
Yes — pigmentary maculopathy, a form of retinal damage, has been linked to long-term use and is now a boxed warning on the label. Risk tracks cumulative exposure rather than the daily dose: reports put it above 10% around 4.5 to 9 years of use (500 to 999 grams total) and above 50% past 1,500 grams total, and the damage may be permanent.
Gastrointestinal effects (nausea, diarrhea) and hair loss each occur in around 4% of people, along with headache. It also has a mild anticoagulant effect, so it's used cautiously alongside blood thinners.
Chemically it's the same sulfated polysaccharide, but the products differ. Cartrophen Vet is registered in Australia specifically for osteoarthritis in dogs, reviewed by the veterinary regulator rather than the human therapeutics regulator, and no canine dosing regimen appears in the human clinical literature behind Elmiron.
No. Both the oral capsules (Elmiron) and the veterinary injectable form are stored at room temperature, with a shelf life of three years or more, and no separate instructions apply once a pack is opened.